期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Aspirin suppresses growth of human gastric carcinoma cell by inhibiting survivin expression 被引量:9
1
作者 Li Yang huaijun zhu +5 位作者 Dongxiao Liu Song Liang Hao Xu Jie Chen Xuerong Wang Zekuan Xu 《The Journal of Biomedical Research》 CAS 2011年第4期246-253,共8页
Regular use of aspirin (ASA) could reduce the risk of gastric cancer although the precise mechanism remains unclear. Down-regulation of survivin may be one of the cyclooxygenase-independent mechanisms whereby ASA in... Regular use of aspirin (ASA) could reduce the risk of gastric cancer although the precise mechanism remains unclear. Down-regulation of survivin may be one of the cyclooxygenase-independent mechanisms whereby ASA induces apoptosis of gastric cancer cell. In this study, we investigated the effect of ASA on the growth, apoptosis and survivin expression of gastric cancer cell line SGC7901. The survival of cells treated with 3.0 and 10.0 mmol/L ASA for 24 h was decreased by 44.6% and 88.5%, respectively. ASA at 3.0 mmol/L inhibited the viability of SGC7901 cells in a time-dependent manner. Apoptosis analysis showed similar results with MTT assay. ASA at 3.0 and 10.0 mmol/L decreased the mRNA transcript levels of survivin and reduced survivin protein levels in SGC7901 cells also in a time-dependent manner. Our findings indicated that ASA inhibited the proliferation of SGC7901 by suppressing survivin at both the transcriptional and translational level. 展开更多
关键词 ASPIRIN SURVIVIN gastric cancer APOPTOSIS
下载PDF
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B,endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society 被引量:3
2
作者 XIAOFEN LIU CHENRONG HUANG +23 位作者 PHILLIP JBERGEN JIAN LI JINGJING ZHANG YIJIAN CHEN YONGCHUAN CHEN BEINING GUO FUPIN HU JINFANG HU LINLIN HU XIN LI HONGQIANG QIU HUA SHAO TONGWEN SUN YU WANG PING XU JING YANG YONG YANG ZHENWEI YU BIKUI ZHANG huaijun zhu XIAOCONG ZUO YI ZHANG LIYAN MIAO JING ZHANG 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2023年第2期130-142,共13页
Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,became available in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk t... Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,became available in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk toxicity,treatment failure,and emergence of resistance,there is an urgent clinical need to perform therapeutic drug monitoring(TDM)to optimize the use of polymyxin B.It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidence for their rational use.We report a consensus on TDM guidelines for polymyxin B,as endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society.The consensus panel was composed of clinicians,pharmacists,and microbiologists from different provinces in China and Australia who made recommendations regarding target concentrations,sample collection,reporting,and explanation of TDM results.The guidelines provide the first-ever consensus on conducting TDM of polymyxin B,and are intended to guide optimal clinical use. 展开更多
关键词 Polymyxin B Therapeutic drug monitoring(TDM) PHARMACOKINETICS Clinical efficacy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部